📋 Tender Overview
The DAK-Gesundheit intends to conclude non-exclusive discount agreements for pharmaceuticals under § 130a Abs. 8 SGB V, specifically for the active ingredient Nadroparin (ATC B01AB06). The agreements will be established with interested pharmaceutical companies until the new discount agreements come into effect on November 1, 2026, and will last until October 31, 2028, with an option for a 12-month extension. The process is open to all pharmaceutical companies, allowing them to enter into framework agreements under the same conditions throughout the contract duration. Nadroparin, ATC B01AB06
